• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估措施在轻度/轻度至中度阿尔茨海默病患者中的概念相关性。

The conceptual relevance of assessment measures in patients with mild/mild-moderate Alzheimer's disease.

作者信息

Hartry Ann, Aldhouse Natalie V J, Al-Zubeidi Tamara, Sanon Myrlene, Stefanacci Richard G, Knight Sarah L

机构信息

Lundbeck, Deerfield, IL, USA.

DRG Abacus, Manchester, UK.

出版信息

Alzheimers Dement (Amst). 2018 Aug 10;10:498-508. doi: 10.1016/j.dadm.2018.07.006. eCollection 2018.

DOI:10.1016/j.dadm.2018.07.006
PMID:30320202
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6180432/
Abstract

INTRODUCTION

This study aims to evaluate the conceptual relevance of four measures of disease activity in patients with mild/mild-moderate Alzheimer's disease (AD): (1) the Alzheimer's Disease Assessment Scale-Cognitive Subscale; (2) the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory; (3) the Neuropsychiatry Inventory; and (4) the Dependence Scale.

METHODS

A conceptual model depicting patient experience of mild AD was developed via literature review; concepts were compared with the items of the four measures. Relevance of the concepts included in the four measures was evaluated by patients with mild AD in a survey and follow-up interviews.

RESULTS

The four measures assessed few of the symptoms/impacts of mild AD identified within the literature. Measured items addressing emotional impacts were deemed most relevant by participants but were included in the measures only superficially.

DISCUSSION

The four assessment measures do not appear to capture the concepts most relevant to/important to patients with mild/mild-moderate AD.

摘要

引言

本研究旨在评估四种疾病活动测量方法对于轻度/轻度至中度阿尔茨海默病(AD)患者的概念相关性:(1)阿尔茨海默病评估量表 - 认知分量表;(2)阿尔茨海默病协作研究 - 日常生活活动量表;(3)神经精神科问卷;以及(4)依赖量表。

方法

通过文献综述构建了一个描述轻度AD患者体验的概念模型;将这些概念与四种测量方法的项目进行比较。轻度AD患者在一项调查和后续访谈中对四种测量方法中包含的概念的相关性进行了评估。

结果

这四种测量方法评估的文献中确定的轻度AD的症状/影响很少。参与者认为涉及情绪影响的测量项目最相关,但这些项目仅在测量方法中被表面地包含。

讨论

这四种评估方法似乎并未涵盖与轻度/轻度至中度AD患者最相关/最重要的概念。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea44/6180432/8555703546c1/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea44/6180432/6a3e0a1b6714/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea44/6180432/8555703546c1/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea44/6180432/6a3e0a1b6714/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea44/6180432/8555703546c1/gr2.jpg

相似文献

1
The conceptual relevance of assessment measures in patients with mild/mild-moderate Alzheimer's disease.评估措施在轻度/轻度至中度阿尔茨海默病患者中的概念相关性。
Alzheimers Dement (Amst). 2018 Aug 10;10:498-508. doi: 10.1016/j.dadm.2018.07.006. eCollection 2018.
2
Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease.阿尔茨海默病全病程临床结局评估的技术综述
Neurol Ther. 2023 Apr;12(2):571-595. doi: 10.1007/s40120-023-00443-2. Epub 2023 Feb 15.
3
4
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.三期 solanezumab 试验:轻度阿尔茨海默病患者的次要结局。
Alzheimers Dement. 2016 Feb;12(2):110-120. doi: 10.1016/j.jalz.2015.06.1893. Epub 2015 Aug 1.
5
Assessing what matters most to patients with or at risk for Alzheimer's and care partners: a qualitative study evaluating symptoms, impacts, and outcomes.评估患有或有阿尔茨海默病风险的患者及其护理伙伴最关心的问题:一项评估症状、影响和结果的定性研究。
Alzheimers Res Ther. 2020 Jul 30;12(1):90. doi: 10.1186/s13195-020-00659-6.
6
Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.轻度认知障碍和轻度阿尔茨海默病中阿尔茨海默病评估量表-认知子量表变体:随时间的变化及强化策略的影响
Alzheimers Res Ther. 2016 Feb 12;8:8. doi: 10.1186/s13195-016-0170-5.
7
Sixteen-Week Interventional Study to Evaluate the Clinical Effects and Safety of Rivastigmine Capsules in Chinese Patients with Alzheimer's Disease.评估卡巴拉汀胶囊对中国阿尔茨海默病患者临床疗效和安全性的16周干预性研究。
J Alzheimers Dis. 2019;72(4):1313-1322. doi: 10.3233/JAD-190791.
8
Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.阿尔茨海默病轻度与中度阶段:胆碱酯酶抑制剂治疗常规临床环境中的三年结局
Alzheimers Res Ther. 2016 Feb 17;8:7. doi: 10.1186/s13195-016-0174-1.
9
Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort.使用认知-功能综合评估早期痴呆患者的认知和日常功能:来自 Catch-Cog 研究队列的发现。
Alzheimers Res Ther. 2019 May 15;11(1):45. doi: 10.1186/s13195-019-0500-5.
10
Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.评价新型磷酸二酯酶 9 抑制剂 BI 409306 口服制剂在伴有前驱期和轻度阿尔茨海默病的患者中进行的两项随机对照 2 期研究中的疗效、安全性和耐受性。
Alzheimers Res Ther. 2019 Feb 12;11(1):18. doi: 10.1186/s13195-019-0467-2.

引用本文的文献

1
Qualitative research and literature review support the integrated Alzheimer's Disease Rating Scale (iADRS) content validity in early symptomatic AD.定性研究和文献综述支持综合阿尔茨海默病评定量表(iADRS)在早期症状性阿尔茨海默病中的内容效度。
J Prev Alzheimers Dis. 2025 Apr;12(4):100101. doi: 10.1016/j.tjpad.2025.100101. Epub 2025 Mar 4.
2
Understanding treatment goals and their application in clinical trial design for patients with Alzheimer disease and caregivers.了解阿尔茨海默病患者及其照料者的治疗目标及其在临床试验设计中的应用。
Drugs Context. 2024 Apr 29;13. doi: 10.7573/dic.2023-11-6. eCollection 2024.
3
Assessing What Matters to People Affected by Alzheimer's Disease: A Quantitative Analysis.

本文引用的文献

1
Measuring cognition and function in the preclinical stage of Alzheimer's disease.在阿尔茨海默病临床前阶段测量认知与功能。
Alzheimers Dement (N Y). 2018 Feb 13;4:64-75. doi: 10.1016/j.trci.2018.01.003. eCollection 2018.
2
Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms.阿尔茨海默病的神经精神症状:新的治疗模式。
Alzheimers Dement (N Y). 2017 Aug 5;3(3):440-449. doi: 10.1016/j.trci.2017.07.001. eCollection 2017 Sep.
3
On the path to 2025: understanding the Alzheimer's disease continuum.
评估对阿尔茨海默病患者重要的事项:一项定量分析。
Neurol Ther. 2023 Apr;12(2):505-527. doi: 10.1007/s40120-023-00445-0. Epub 2023 Feb 10.
4
Outcome measures for Alzheimer's disease: A global inter-societal Delphi consensus.阿尔茨海默病的结局评估指标:全球跨学会德尔菲共识。
Alzheimers Dement. 2023 Jun;19(6):2707-2729. doi: 10.1002/alz.12945. Epub 2023 Feb 7.
5
The Patient Voice: Exploring Treatment Preferences in Participants with Mild Cognitive Concerns to Inform Regulatory Decision Making.患者声音:探索轻度认知障碍参与者的治疗偏好,为监管决策提供信息。
Patient. 2022 Sep;15(5):551-564. doi: 10.1007/s40271-022-00576-w. Epub 2022 Apr 18.
6
Assessing what matters most to patients with or at risk for Alzheimer's and care partners: a qualitative study evaluating symptoms, impacts, and outcomes.评估患有或有阿尔茨海默病风险的患者及其护理伙伴最关心的问题:一项评估症状、影响和结果的定性研究。
Alzheimers Res Ther. 2020 Jul 30;12(1):90. doi: 10.1186/s13195-020-00659-6.
7
Enhancing 'meaningfulness' of functional assessments: UK adaptation of the Amsterdam IADL questionnaire.增强功能评估的“意义”:英国对阿姆斯特丹 IADL 问卷的适应性调整。
Int Psychogeriatr. 2021 Jan;33(1):39-50. doi: 10.1017/S1041610219001881. Epub 2020 Apr 15.
通往2025之路:理解阿尔茨海默病连续体
Alzheimers Res Ther. 2017 Aug 9;9(1):60. doi: 10.1186/s13195-017-0283-5.
4
Function and clinical meaningfulness of treatments for mild Alzheimer's disease.轻度阿尔茨海默病治疗的作用及临床意义
Alzheimers Dement (Amst). 2016 Mar 10;2:105-12. doi: 10.1016/j.dadm.2016.02.006. eCollection 2016.
5
Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.轻度认知障碍和轻度阿尔茨海默病中阿尔茨海默病评估量表-认知子量表变体:随时间的变化及强化策略的影响
Alzheimers Res Ther. 2016 Feb 12;8:8. doi: 10.1186/s13195-016-0170-5.
6
Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review.轻度认知障碍与工具性日常生活活动能力缺陷:系统综述。
Alzheimers Res Ther. 2015 Mar 18;7(1):17. doi: 10.1186/s13195-015-0099-0. eCollection 2015.
7
Quality of life as an outcome in Alzheimer's disease and other dementias--obstacles and goals.阿尔茨海默病及其他痴呆症的生活质量结局——障碍与目标
BMC Neurol. 2009 Aug 25;9:47. doi: 10.1186/1471-2377-9-47.
8
A systematic review of Instrumental Activities of Daily Living scales in dementia: room for improvement.痴呆症日常生活能力量表的系统评价:仍有改进空间
J Neurol Neurosurg Psychiatry. 2009 Jan;80(1):7-12. doi: 10.1136/jnnp.2008.155838.
9
Clinical trial design issues in mild to moderate Alzheimer disease.轻度至中度阿尔茨海默病的临床试验设计问题
Cogn Behav Neurol. 2008 Dec;21(4):197-201. doi: 10.1097/WNN.0b013e318190cf75.
10
The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial.在一项开放标签试验中,接受多奈哌齐治疗的阿尔茨海默病患者中,阿尔茨海默病评估量表-认知部分(ADAS-Cog)变化的临床意义。
BMC Neurol. 2007 Aug 30;7:26. doi: 10.1186/1471-2377-7-26.